Partner companies Eisai and Biogen recently announced promising clinical trial results for their new Alzheimer’s drug lecanemab. Over 18 months, patients treated with lecanemab experienced slower symptom progression than the placebo group. These results have been described as a ‘historic moment for dementia research’—but what do they really mean for patients?